Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 33-36

  Bruno, R ^a   Sacchi, P ^a   Cima, S ^a   Maiocchi, L ^a   Novati, S ^a   Filice, G ^a   Fagiuoli, S ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

HCV; peginterferon; pharmacodynamic; pharmacokinetic

Indexed keywords

BETA 2 MICROGLOBULIN; MACROGOL; NEOPTERIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HALF-LIFE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84855662382     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01519.x     Document Type: Article

References (16)

1. Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8 (24): 2139-2157. (Pubitemid 35203229)
2. Foster GR,. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20 (8): 825-830. (Pubitemid 39424889)
3. Schering-Plough Corporation. PegIntron- (peginterferon alfa-2b): full prescribing information [online]. Available from URL: (accessed 8 December 2009).
4. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12 (2): 195-202. (Pubitemid 32235471)
5. Roche Laboratories Inc. Pegasys- (peginterferon alfa-2a): complete product information [online]. Available from URL: (accessed 8 December 2009).
6. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon 162 Foster 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (2) alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45 (2): 204-213.
7. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004; 9 (4): 491-497. (Pubitemid 39150205)
8. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14 (10): 721-729. (Pubitemid 47414932)
9. Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003; 10 (4): 271-276. (Pubitemid 36801913)
10. Baron S, Tyring SK, Fleischmann Jr WR, et al. The interferons.mechanisms of action and clinical applications. JAMA 1991; 266 (10): 1375-1383.
11. Sen GC,. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-281. (Pubitemid 32978106)
12. Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEGinterferon- alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem 2005; 16 (3): 518-527. (Pubitemid 40696042)
13. Keating GM, Curran MP,. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63 (7): 701-730. (Pubitemid 36408076)
14. Shindo M, Hamada K, Morikawa T, et al. In vivo interferon system assessed by 20-50 oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatol Res 2008; 38 (12): 1213-1220.
15. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized,controlled study. Aliment Pharmacol Ther 2007; 26 (3): 369-376. (Pubitemid 47063155)
16. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639. (Pubitemid 47436107)